Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00020670 · ClinicalTrials.gov registry record · Early Phase 1
Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia
A Early Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
NCT00020670 is a Early Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 9 participants.
The verdict
NCT00020670, a Early Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having unfavorable genetics \[t(4;11) or t(9;22)\] have dismal prognosis. For these patients, novel therapeutic approaches such as immunotherapy are needed. In this clinical trial, investigators evaluate whether it is feasible to make a vaccine from leukemia cells and whether this vaccine enables direct immunity against cancer cells in patients.
Interventions
- BIOLOGICAL CD 40
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2001-02-20 |
| Est. Completion | 2003-07-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00020670
The ClinicalTrials.gov registry entry for NCT00020670 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD 40 is the first listed.
NCT00020670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00020670 about?
NCT00020670 is a clinical study titled "Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia". The prognosis for children and adults with acute lymphoblastic leukemia (ALL) has improved significantly over the years. Nevertheless, patients who experience disease relapse or induction failure along with patients having unfavorable genetics \[t(4;11) or t(9;22)\] have dismal prognosis. For these ...
What is the current status of trial NCT00020670?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2001-02-20. Estimated completion is 2003-07-01.
What interventions are being tested in trial NCT00020670?
The interventions under investigation include: CD 40 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00020670?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.